Showing results (11-20 of 23) with videos related to
Sort By:
Pageof 3
Orphanet Journal of Rare Diseases|July 23, 2020
Wound closure in epidermolysis bullosa: data from the vehicle arm of the phase 3 ESSENCE StudyDedee F Murrell, Amy S Paller, Christine Bodemer, et al.Paediatric Drugs|June 13, 2022
Efficacy of Secukinumab Across Subgroups and Overall Safety in Pediatric Patients with Moderate to Severe Plaque Psoriasis: Week 52 Results from a Phase III Randomized StudyNina Magnolo, Külli Kingo, Vivian Laquer, et al.Orphanet Journal of Rare Diseases|June 25, 2020
Efficacy and tolerability of the investigational topical cream SD-101 (6% allantoin) in patients with epidermolysis bullosa: a phase 3, randomized, double-blind, vehicle-controlled trial (ESSENCE study)Amy S Paller, John Browning, Milos Nikolic, et al.Dermatology and Therapy|January 8, 2025
Tapinarof Improved Outcomes and Sleep for Patients and Families in Two Phase 3 Atopic Dermatitis Trials in Adults and ChildrenEric L Simpson, Adelaide A Hebert, John Browning, et al.Journal of the American Academy of Dermatology|September 23, 2021
A phase 3 open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week resultsNina Magnolo, Külli Kingo, Vivian Laquer, et al.Marine Pollution Bulletin|March 16, 2021
Mortality of a juvenile Magellanic penguin (Spheniscus magellanicus, Spheniscidae) associated with the ingestion of a PFF-2 protective mask during the Covid-19 pandemicHugo Gallo Neto, Carla Gomes Bantel, John Browning, et al.Dermatologic Therapy|December 26, 2021
Secukinumab demonstrates efficacy, safety, and tolerability upon administration by 2 ml autoinjector in adult patients with plaque psoriasis: 52-week results from MATURE, a randomized, placebo-controlled trialBardur Sigurgeirsson, John Browning, Stephen Tyring, et al.International Journal of Dermatology|April 29, 2024
Importance of treating acne sequelae in skin of color: 6-month phase IV study of trifarotene with an appropriate skincare routine including UV protection in acne-induced post-inflammatory hyperpigmentationAndrew Alexis, James Q Del Rosso, Seth Forman, et al.Journal of the American Academy of Dermatology|May 18, 2025
Skin clearance, duration of treatment-free interval, and safety of tapinarof cream 1% once daily: Results from ADORING 3, a 48-week phase 3 open-label extension trial in adults and children down to 2 years of age with atopic dermatitisRobert Bissonnette, Linda Stein Gold, Leon Kircik, et al.American Journal of Clinical Dermatology|May 14, 2022
Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE)Andrew Blauvelt, Emma Guttman-Yassky, Amy S Paller, et al.Pageof 3